Please assess the completion status of the following clinical trial:

Trial Title: Melatonin as a Circadian Clock Regulator, Neuromodulator and Myelo-protector in Adjuvant Breast Cancer Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Diagnosed with breast cancer~* Indicated for the adjuvant treatment for breast cancer~* Between 18 years and 75 years~* Alphabetized~Exclusion Criteria:~* Undergone chemotherapy or radiotherapy before inclusion in the study.~* Pregnant~* Epilepsy~* Brain Stroke~* Multiple sclerosis~* BMI above 45 kg / m 2

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Melatonin (Type: ACTIVE_COMPARATOR): Melatonin 20 mg Oral Capsules, once a day at bedtime
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Oral Capsules, once a day at bedtime

Based on this trial design, predict the completion outcome and termination type (if applicable).